Literature DB >> 10647954

Musculoskeletal and systemic reactions to biological therapeutic agents.

R A Watts.   

Abstract

Autoimmune disease, in particular systemic lupus erythematosus (SLE), can be induced by drugs. Over the past couple of years biologic agents have become available for the treatment of inflammatory disease; simultaneously, researchers have realized that these drugs can not only suppress autoimmune disease but may also potentiate it. Interferon-alpha and interferon-beta both may induce autoimmune disease, but this is more frequent with interferon-alpha. Therapy to block tumor necrosis factor-alpha, either with monoclonal antibodies or fusion proteins, has been associated with the development of antinuclear antibodies, but only rarely with clinical development of SLE. None of the three reported cases of SLE occuring after anti-tumor necrosis factor-alpha therapy has developed major organ involvement. The continued use of biologic agents will provide interesting insights into the pathogenesis of autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10647954     DOI: 10.1097/00002281-200001000-00008

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  4 in total

1.  Possible involvement of interferon beta in post-operative vasculitis restricted to the tumour bed: a case report.

Authors:  Tatsuya Abe; Kenji Sugita; Masaki Morishige; Kouhei Ohnishi; Keisuke Ishii; Tohru Kamida; Takamitsu Hikawa; Minoru Fujiki; Hidenori Kobayashi; Kenji Kashima; Shigeo Yokoyama
Journal:  Neurosurg Rev       Date:  2008-07-11       Impact factor: 3.042

2.  The safety of etanercept for the treatment of plaque psoriasis.

Authors:  Kim A Papp
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

Review 3.  Animal Models of Interferon Signature Positive Lupus.

Authors:  Haoyang Zhuang; Christopher Szeto; Shuhong Han; Lijun Yang; Westley H Reeves
Journal:  Front Immunol       Date:  2015-06-05       Impact factor: 7.561

4.  Evaluating the safety of β-interferons in MS: A series of nested case-control studies.

Authors:  Hilda J I de Jong; Elaine Kingwell; Afsaneh Shirani; Jan Willem Cohen Tervaert; Raymond Hupperts; Yinshan Zhao; Feng Zhu; Charity Evans; Mia L van der Kop; Anthony Traboulsee; Paul Gustafson; John Petkau; Ruth Ann Marrie; Helen Tremlett
Journal:  Neurology       Date:  2017-05-12       Impact factor: 9.910

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.